Teva Pharmaceuticals International GmbH v. Eli Lilly and Company, No. 24-1094 (Fed. Cir. Apr. 16, 2026)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc. (collectively, “Teva”) su ed Eli Lilly and Company (“Lilly”) for infringing Teva’s U .S. Pa- tent Nos. 8,586,045 (“the ’045 patent”), 9,884,907 (“the ’907 patent”), and 9,884,908 (“the ’908 patent”) (c ollec- tively, the “headache patents”). A jury found that Lilly willfully infringed the headache patents and failed to prove their asserted claims i nvalid. The U.S.